Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TRDA

Entrada Therapeutics Inc

Dec 13 • 04:00PM ET

17.66

Dollar change -0.46
Percentage change -2.54	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: IWM VTI VXF IWN SCHA VTWO FDM IWC VHT AVSC

Scroll to Statements

Index	RUT	P/E	11.08	EPS (ttm)	1.59	Insider Own	41.75%	Shs Outstand	37.40M	Perf Week	-18.20%
Market Cap	644.06M	Forward P/E	-	EPS next Y	-3.09	Insider Trans	-1.17%	Shs Float	21.80M	Perf Month	-11.52%
Income	54.95M	PEG	-	EPS next Q	-0.67	Inst Own	53.12%	Short Float	7.00%	Perf Quarter	21.37%
Sales	215.23M	P/S	2.99	EPS this Y	626.32%	Inst Trans	2.22%	Short Ratio	11.11	Perf Half Y	11.91%
Book/sh	11.30	P/B	1.56	EPS next Y	-393.48%	ROA	10.57%	Short Interest	1.53M	Perf Year	28.62%
Cash/sh	12.32	P/C	1.43	EPS next 5Y	-	ROE	16.43%	52W Range	11.35 - 21.79	Perf YTD	17.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-5.52%	ROI	11.54%	52W High	-18.95%	Beta	-0.17
Dividend TTM	-	Quick Ratio	6.59	Sales past 5Y	0.00%	Gross Margin	98.39%	52W Low	55.59%	ATR (14)	0.93
Dividend Ex-Date	-	Current Ratio	6.59	EPS Y/Y TTM	337.27%	Oper. Margin	26.85%	RSI (14)	39.06	Volatility	5.72% 4.76%
Employees	159	Debt/Eq	0.15	Sales Y/Y TTM	146.92%	Profit Margin	25.53%	Recom	1.00	Target Price	25.67
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-133.87%	Payout	-	Rel Volume	0.81	Prev Close	18.12
Sales Surprise	58.91%	EPS Surprise	51.92%	Sales Q/Q	-55.25%	Earnings	Nov 05 BMO	Avg Volume	137.35K	Price	17.66
SMA20	-8.51%	SMA50	-3.77%	SMA200	12.89%	Trades		Volume	111,157	Change	-2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
07:00AM	Loading…
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
09:55AM	Loading…
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
07:01AM	Loading…
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%
May-12-22 07:00AM	Entrada Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.25%
May-11-22 09:30AM	Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV) Therapeutics at TIDES USA 2022 (GlobeNewswire) -9.44%
May-10-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.84%
Mar-15-22 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +9.78%
Feb-23-22 08:00AM	Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference (GlobeNewswire) -17.21%
Feb-04-22 01:27PM	We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth (Simply Wall St.) +12.79%
Feb-03-22 09:38AM	5AM Venture Management, LLC Buys Pear Therapeutics Inc, Entrada Therapeutics Inc, Sells ... (GuruFocus.com)
Jan-05-22 08:00AM	Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel (GlobeNewswire) -15.44%
Dec-17-21 08:00AM	Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Dec-09-21 07:00AM	Entrada Therapeutics Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Nov-18-21 08:00AM	Entrada Therapeutics to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-05-21 08:32AM	4 Stocks Insiders Are Buying (Benzinga)
Nov-02-21 04:26PM	Entrada Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +13.19%
Oct-28-21 10:21PM	Entrada Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Option Exercise	2.10	5,000	10,500	78,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Option Exercise	2.10	1,000	2,100	74,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Sale	20.00	5,000	99,978	73,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Sale	19.97	1,000	19,970	73,849	Dec 03 05:26 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 03 '24	Sale	20.15	11,703	235,786	144,997	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 02 '24	Sale	20.26	4,088	82,834	156,700	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 29 '24	Sale	20.00	100	2,000	160,788	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 13 '24	Sale	20.04	2,700	54,109	160,888	Nov 13 04:49 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 11 '24	Sale	20.01	1,409	28,191	163,588	Nov 13 04:49 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Option Exercise	2.10	6,000	12,600	82,486	Nov 13 04:47 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Sale	19.98	8,637	172,562	73,849	Nov 13 04:47 PM
NATARAJAN SETHURAMAN	Officer	Nov 11 '24	Proposed Sale	19.82	18,762	371,863		Nov 12 07:54 AM
KORY WENTWORTH	Officer	Nov 11 '24	Proposed Sale	19.82	14,637	290,105		Nov 12 07:53 AM
Sethuraman Natarajan	President, Research & Develop.	Nov 06 '24	Sale	18.85	12,299	231,776	164,997	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 05 '24	Sale	18.18	5,171	94,006	177,296	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 04 '24	Sale	18.02	749	13,498	182,467	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Oct 16 '24	Sale	18.00	600	10,800	183,216	Oct 18 04:31 PM
NATARAJAN SETHURAMAN	Officer	Oct 16 '24	Proposed Sale	17.53	20,057	351,599		Oct 16 04:25 PM
Dowden Nathan J	President & COO	Sep 26 '24	Sale	16.00	847	13,552	125,149	Sep 30 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 09 '24	Sale	14.97	3,195	47,832	76,486	Sep 10 04:34 PM
Dowden Nathan J	President & COO	Sep 09 '24	Sale	15.07	1,904	28,690	125,996	Sep 10 04:33 PM
Dowden Nathan J	President & COO	Sep 06 '24	Sale	15.19	399	6,063	127,900	Sep 10 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 09 '24	Sale	15.09	2,642	39,862	183,816	Sep 10 04:32 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 06 '24	Sale	15.24	600	9,141	186,458	Sep 10 04:32 PM
KORY WENTWORTH	Officer	Sep 09 '24	Proposed Sale	14.80	3,195	47,286		Sep 09 04:27 PM
NATHAN DOWDEN	Officer	Sep 06 '24	Proposed Sale	15.39	3,150	48,478		Sep 06 04:19 PM
Dowden Nathan J	President & COO	Aug 16 '24	Option Exercise	1.74	20,000	34,800	157,204	Aug 20 04:33 PM
Dowden Nathan J	President & COO	Aug 16 '24	Sale	16.27	27,097	440,801	130,107	Aug 20 04:33 PM
NATHAN DOWDEN	Officer	Aug 16 '24	Proposed Sale	16.26	27,097	440,597		Aug 16 04:25 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 15 '24	Sale	18.00	638	11,484	188,814	Jul 16 04:43 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 12 '24	Sale	18.00	600	10,800	189,452	Jul 16 04:43 PM
Doshi Dipal	CEO	Jul 15 '24	Sale	17.81	1,600	28,497	334,475	Jul 16 04:42 PM
Doshi Dipal	CEO	Jul 12 '24	Sale	18.00	300	5,400	336,075	Jul 16 04:42 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 08 '24	Sale	14.95	1,758	26,282	81,412	Jul 10 04:34 PM
Doshi Dipal	CEO	Jun 13 '24	Sale	16.17	1,000	16,174	336,375	Jun 14 04:32 PM
KIM PETER S	Director	Jun 03 '24	Option Exercise	6.06	11,918	72,223	104,330	Jun 05 04:31 PM
Sethuraman Natarajan	Chief Scientific Officer	May 20 '24	Sale	15.19	9,675	146,944	190,052	May 20 05:26 PM
Sethuraman Natarajan	Chief Scientific Officer	May 17 '24	Sale	15.14	8,305	125,751	199,727	May 20 05:26 PM
Sethuraman Natarajan	Chief Scientific Officer	May 16 '24	Sale	15.00	1,000	15,000	208,032	May 20 05:26 PM
Doshi Dipal	CEO	May 16 '24	Sale	15.00	1,800	27,000	338,575	May 20 05:21 PM
Doshi Dipal	CEO	May 17 '24	Sale	15.11	1,200	18,129	337,375	May 20 05:21 PM
KIM PETER S	Director	May 14 '24	Buy	14.59	25,000	364,672	92,412	May 16 04:33 PM
KIM PETER S	Director	May 08 '24	Buy	14.04	2,276	31,965	65,212	May 10 04:35 PM
KIM PETER S	Director	May 09 '24	Buy	14.25	2,200	31,341	67,412	May 10 04:35 PM
KIM PETER S	Director	Apr 08 '24	Buy	13.57	2,600	35,290	62,936	Apr 10 04:35 PM
KIM PETER S	Director	Mar 28 '24	Buy	13.75	1,512	20,794	60,336	Apr 01 04:31 PM
KIM PETER S	Director	Mar 22 '24	Buy	13.76	3,118	42,901	52,894	Mar 26 05:57 PM
KIM PETER S	Director	Mar 25 '24	Buy	13.36	3,180	42,472	56,074	Mar 26 05:57 PM
KIM PETER S	Director	Mar 26 '24	Buy	13.64	2,750	37,509	58,824	Mar 26 05:57 PM
KIM PETER S	Director	Mar 20 '24	Buy	12.66	1,128	14,281	49,072	Mar 21 04:31 PM
KIM PETER S	Director	Mar 19 '24	Buy	12.66	900	11,397	47,944	Mar 21 04:31 PM
KIM PETER S	Director	Mar 21 '24	Buy	13.24	704	9,318	49,776	Mar 21 04:31 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 15 '24	Option Exercise	2.10	9,000	18,900	83,170	Mar 19 04:33 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 06 '24	Sale	12.31	4,086	50,285	74,170	Mar 08 04:36 PM
Dowden Nathan J	President & COO	Mar 06 '24	Sale	12.32	1,826	22,499	137,204	Mar 08 04:34 PM
Doshi Dipal	CEO	Feb 15 '24	Sale	15.00	1,000	15,000	243,279	Feb 20 04:37 PM
Doshi Dipal	CEO	Jan 16 '24	Sale	15.99	1,000	15,990	244,279	Jan 18 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Option Exercise	2.10	10,206	21,433	59,777	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Option Exercise	2.10	2,200	4,620	51,771	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Option Exercise	2.10	94	197	49,665	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 22 '23	Sale	15.69	10,206	160,124	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 21 '23	Sale	15.07	2,200	33,155	49,571	Dec 26 04:35 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 26 '23	Sale	16.67	94	1,567	49,571	Dec 26 04:35 PM
Doshi Dipal	President and CEO	Dec 20 '23	Sale	15.00	1,000	15,000	245,279	Dec 22 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience